Taltz requires the fewest injections among IL-17A antagonists for patients with PsA and coexistent moderate to severe PsO1,2
Injections during first year
For Taltz: Starter dose (two 80 mg injections), followed by one 80 mg injection every 2 weeks for 12 weeks, then one 80 mg injection every 4 weeks thereafter.
For Cosentyx: Two 150 mg injections every week for 5 weeks, then two 150 mg injections every 4 weeks thereafter.
This presentation is not intended to make comparative claims of safety or efficacy. Please refer to the Cosentyx Prescribing Information for dosing.
Cosentyx® is a registered trademark of Novartis AG Corporation.
IL-17A=interleukin-17A; PsA=psoriatic arthritis; PsO=psoriasis.
Taltz dosing for PsA without coexistent moderate to severe PsO
CONVENIENT DOSING FOR PATIENTS WITH AS AND PsA*
Start patients quickly with a 1-day starting dose, and continue with a once-monthly† schedule1
PsA=psoriatic arthritis; PsO=psoriasis; AS=ankylosing spondylitis; nr-axSpA=non-radiographic axial spondyloarthritis.
SELECT IMPORTANT SAFETY INFORMATION: PRE-TREATMENT EVALUATION FOR TUBERCULOSISEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
AS=ankylosing spondylitis; nr-axSpA=non-radiographic axial spondyloarthritis; PsA=psoriatic arthritis.
References: 1. Taltz [package insert]. Indianapolis, IN: Lilly USA, LLC. 2. Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021.